Nippon India Pharma Fund Direct-Growth
NAV
₹538.1034
as on 03 Apr 2025, 11:11 PM
₹8.1786(1.54%)
Last Change
Scheme Information
Nippon India Pharma Fund Direct-Growth
as of 28 Feb 2025, 05:30 AM
₹7,637.04 Cr
0.91%
1.11%
Open-End
Growth
Exit load of 1% if redeemed within 1 month.
BSE Healthcare Total Return Index
View
Sectors Holding in this Mutual Fund
Healthcare
98.88%
₹7,551.50 Cr
Others
1.12%
₹85.53 Cr
Healthcare
98.88%
₹7,551.50 Cr
Others
1.12%
₹85.53 Cr
Sun Pharmaceutical Industries Ltd.
13.47%
₹1,028.71 Cr
Divi's Laboratories Ltd.
8.39%
₹640.75 Cr
Lupin Ltd.
7.67%
₹585.76 Cr
Cipla Ltd.
6.20%
₹473.50 Cr
Dr. Reddy's Laboratories Ltd.
6.05%
₹462.04 Cr
Others
58.22%
₹4,446.28 Cr
Sun Pharmaceutical Industries Ltd.
13.47%
₹1,028.71 Cr
Divi's Laboratories Ltd.
8.39%
₹640.75 Cr
Lupin Ltd.
7.67%
₹585.76 Cr
Cipla Ltd.
6.20%
₹473.50 Cr
Dr. Reddy's Laboratories Ltd.
6.05%
₹462.04 Cr
Others
58.22%
₹4,446.28 Cr
Funds in this Category
This fund's returns: 19.59%
SBI Healthcare Opportunities Fund Direct Plan-Growth
Min. Investment
₹500
24.33
Category Returns
15.79%
24.33%
3Y Returns
24.33 %
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
Min. Investment
₹100
24.00
Category Returns
15.79%
24.33%
3Y Returns
24.00 %
DSP Healthcare Fund Direct - Growth
Min. Investment
₹100
21.19
Category Returns
15.79%
24.33%
3Y Returns
21.19 %
About Nippon India Pharma Fund Direct-Growth
Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is 13.23%, in last 3 years is 71.31% and 670.21% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
AUM: | ₹7,637.04 Cr |
Category: | Equity: Sectoral-Pharma |
Launch Date: | Invalid date |
Fund Type: | Open-End |
AMC Information
Nippon India Mutual Fund
Address
Investment Performance
₹ 1,00,000
would have given a return of
₹1,10,871
₹1,21,647
₹1,66,749
₹1,71,305
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
Profit (absolute return)
₹71,305
71.31%
Investment Returns
Scheme Riskometer
Investors understand that their principal will be at very high risk